Samer Abbas, MD
Interventional Cardiology · East Chicago, INNPI 1568481182
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 67.3% of it on its own, with 59 other manufacturers making up the rest. Among interventional cardiology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,571 payments — averaging $251.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$266K
- Edwards Lifesciences$46K
- Boston Scientific$24K
- Cardiovascular Systems Inc.$12K
- Biosense Webster, Inc.$8K
- Abbott$5K
- plus $34K from 54 others
Across 79 payments — averaging $2941.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$214K
- Bard Peripheral Vascular, Inc.$15K
- Medtronic$3K
What the payments were for
- Consulting fees$62,80616%
- Speaking & faculty fees$210,01453%
- Travel & lodging$54,69514%
- Food & beverage$67,68117%
- Education$400%
- Entertainment$2630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$200,355
- Edwards SAPIEN 3 Transcatheter Heart Valve$19,337
- IN.PACT Admiral$18,295
- HawkOne$14,950
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$14,255
- GENERAL VASCULAR ACCESS$11,983
- Diamondback Coronary$11,141
- TurboHawk$10,724
- Diamondback Peripheral$9,729
- GENERAL - THERAPIES$7,165
- SavvyWire$6,750
- Carto 3$6,725
- FlowMet$4,740
- PK Papyrus$3,914
- Pulsar$3,914
- Astron; Pulsar; AstronPulsar$3,914
- Orsiro$3,914
- PASCAL$2,828
- CoreValve Evolut$2,407
- Passeo$2,000
How this compares
$395,499 in reported general payments places this provider in the 95th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 216 | $319,166 |
| EliquisApixaban | 175 | $213,666 |
| Repatha SureclickEvolocumab | 164 | $134,278 |
| FarxigaDapagliflozin Propanediol | 62 | $77,091 |
| XareltoRivaroxaban | 36 | $51,500 |
| BrilintaTicagrelor | 41 | $45,942 |
| Ranolazine ErRanolazine | 49 | $5,888 |
| ClopidogrelClopidogrel Bisulfate | 548 | $5,827 |
| Atorvastatin Calcium | 491 | $3,554 |
| Metoprolol Succinate | 289 | $2,815 |
| Nebivolol Hcl | 29 | $2,226 |
| Ezetimibe | 106 | $1,855 |
| Nitroglycerin | 29 | $1,774 |
| Carvedilol | 222 | $1,707 |
| Rosuvastatin Calcium | 180 | $1,564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $1,672 | $319,166216 claims |
| PfizerEliquis | $71 | $213,666175 claims |
| AstraZenecaFarxiga, Brilinta | $202 | $123,034103 claims |
| Johnson & JohnsonXarelto | $623 | $51,50036 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in East Chicago
- Dean FerreraEast Chicago$180K
- Amit KakkarEast Chicago$20K
- Arif KhalilEast Chicago$15K
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Muzammil MusaniFort Wayne$184K
- Shashidhar DivakaruniMunster$97K
- Jarrod FrizzellEvansville$86K
- Navneet LatherNoblesville$83K
- Michael BallIndianapolis$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.